 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | lenalidomide subcutaneous prolonged-release (NEX-20A) / Nanexa AB
Trial initiation date: To Assess Safety, Tolerability and PK of NEX-20A, a Subcutaneous Prolonged-release Injection to Healthy Subjects (clinicaltrials.gov) - Oct 31, 2023
P1, N=9, Completed, Sponsor: Nanexa AB
Initiation date: May 2023 --> Nov 2022
- || lenalidomide subcutaneous prolonged-release (NEX-20A) / Nanexa AB
Trial completion, Trial initiation date, Trial primary completion date: To Assess Safety, Tolerability and PK of NEX-20A, a Subcutaneous Prolonged-release Injection to Healthy Subjects (clinicaltrials.gov) - Oct 17, 2023
P1, N=9, Completed, Sponsor: Nanexa AB
Initiation date: May 2023 --> Nov 2022 Recruiting --> Completed | Initiation date: Nov 2022 --> May 2023 | Trial primary completion date: Jun 2023 --> Sep 2023
- || lenalidomide subcutaneous prolonged-release (NEX-20A) / Nanexa AB
Enrollment open: To Assess Safety, Tolerability and PK of NEX-20A, a Subcutaneous Prolonged-release Injection to Healthy Subjects (clinicaltrials.gov) - Dec 19, 2022
P1, N=9, Recruiting, Sponsor: Nanexa AB
Recruiting --> Completed | Initiation date: Nov 2022 --> May 2023 | Trial primary completion date: Jun 2023 --> Sep 2023 Not yet recruiting --> Recruiting
- || lenalidomide subcutaneous prolonged-release (NEX-20A) / Nanexa AB
New P1 trial: To Assess Safety, Tolerability and PK of NEX-20A, a Subcutaneous Prolonged-release Injection to Healthy Subjects (clinicaltrials.gov) - Dec 8, 2022
P1, N=9, Not yet recruiting, Sponsor: Nanexa AB